55,100 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Swedbank AB

Swedbank AB bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 55,100 shares of the company’s stock, valued at approximately $1,378,000. Swedbank AB owned 0.08% of Olema Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new position in Olema Pharmaceuticals during the 4th quarter worth approximately $24,100,000. Kingdon Capital Management L.L.C. acquired a new position in Olema Pharmaceuticals during the 3rd quarter worth approximately $8,361,000. Ameriprise Financial Inc. grew its holdings in Olema Pharmaceuticals by 193.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock worth $4,996,000 after acquiring an additional 773,064 shares in the last quarter. Candriam S.C.A. grew its holdings in Olema Pharmaceuticals by 46.9% during the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock worth $12,235,000 after acquiring an additional 399,273 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Olema Pharmaceuticals by 11.4% during the 4th quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock worth $89,034,000 after acquiring an additional 364,035 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Shawnte Mitchell sold 25,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Trading Down 4.7%

Shares of Olema Pharmaceuticals stock opened at $12.91 on Thursday. The company has a fifty day simple moving average of $14.79 and a 200-day simple moving average of $20.81. Olema Pharmaceuticals, Inc. has a 12-month low of $3.89 and a 12-month high of $36.26. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -6.39 and a beta of 2.05.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). On average, equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OLMA has been the subject of several analyst reports. Jefferies Financial Group initiated coverage on shares of Olema Pharmaceuticals in a report on Thursday, March 19th. They set a “buy” rating and a $40.00 price target for the company. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. The Goldman Sachs Group lowered their price target on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, March 18th. Finally, Citigroup boosted their price target on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.